Physician profile
John Manuel Rivas
NPI 1831412360
$3,934.70
in general payments reported to CMS, 2019-2025
31 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $430 · 2021: $407 · 2022: $619 · 2023: $773 · 2024: $1,278 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,323.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $877.01 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $682.63 | 2020-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $387.90 | 2019-2024 | |
| Celgene Corporation | $268.81 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $268.79 | 2019-2024 | |
| Inari Medical, INC. | $166.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Biotech, INC. | $142.35 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Actelion Pharmaceuticals US, INC. | $141.57 | 2024 | Uptravi, Opsumit |
| Celltrion USA INC. | $118.43 | 2024-2025 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $100.04 | 2021-2024 | Gattex |
| Phathom Pharmaceuticals, INC. | $96.49 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $82.87 | 2021-2023 | Dificid |
| Braintree Laboratories, INC. | $75.65 | 2022-2024 | Suflave, Sutab |
| Mallinckrodt Hospital Products INC. | $69.67 | 2020-2022 | |
| Boston Scientific Corporation | $61.52 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $52.02 | 2024-2025 | Haegarda |
| Madrigal Pharmaceuticals | $44.94 | 2024-2025 | Resmetirom, Rezdiffra |
| Pfizer INC. | $41.45 | 2019-2025 | |
| Olympus America INC. | $41.13 | 2020 | |
| Ethicon US, LLC | $30.81 | 2021 | |
| Genzyme Corporation | $27.35 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $25.42 | 2022-2023 | Riteclip |
| Regeneron Healthcare Solutions, INC. | $21.73 | 2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $21.30 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.63 | 2024 | |
| Ardelyx, INC. | $19.48 | 2024 | Ibsrela |
| Meridian Bioscience INC. | $18.08 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $17.92 | 2023 | Evusheld |
| Pentax of America, INC. | $12.21 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.